Skip to NavigationSkip to content

Bioenvision's leukaemia treatment gains positive opinion

Published on 01/03/06 at 11:20am

Bioenvision has received a positive opinion from the European Medicines Agency for Evoltra (clofarabine), the first drug specifically developed for children with multiple relapsed or refractory leukaemia.

The drug is expected to gain final marketing approval within the next three months to treat acute lymphoblastic leukaemia (ALL) in children who have relapsed or are refractory to at least two prior regimens.

Bioenvision will market Evoltra throughout all 25 member states of the EU and has licensed it to Genzyme to develop and market in the US and Canada under the brand name Clolar.


Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches